公开(公告)号：WO0200692A9

公开(公告)日：2003-05-30

申请号：PCT/US0120858

申请日：2001-06-28

Applicant: INST GENETICS LLC ,  DANA FARBER CANCER INST INC ,  BRIGHAM & WOMENS HOSPITAL

Inventor： FREEMAN GORDON ,  CHERNOVA IRENE ,  CHERNOVA TATYANA ,  MALENKOVICH NELLY ,  WOOD CLIVE ,  LATCHMAN YVETTE ,  SHARPE ARLENE H

IPC: A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  A61P3/10 ,  A61P11/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/08 ,  C07K14/705 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/566 ,  G01N33/573 ,  G01N33/68

CPC classification number: G01N33/6854 ,  G01N33/5014 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/573 ,  G01N2800/52

Abstract: The invention provides isolated nucleic acid molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.

Abstract translation: 本发明提供了分离的核酸分子，称为PD-L2核酸分子，其编码作为PD-1配体的新型B7相关分子。 本发明还提供了反义核酸分子，含有PD-L2核酸分子的重组表达载体，导入了表达载体的宿主细胞，以及导入或破坏了PD-L2基因的非人转基因动物。 本发明进一步提供了分离的PD-L2多肽，融合蛋白，抗原肽和抗PD-L2抗体。 本发明还提供了促进或抑制PD-L2与PD-1相互作用的方法。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：WO0200730A9

公开(公告)日：2003-07-10

申请号：PCT/US0120964

申请日：2001-06-28

Applicant: INST GENETICS LLC ,  DANA FARBER CANCER INST INC

Inventor： FREEMAN GORDON ,  CHERNOVA IRENE ,  CHERNOVA TATYANA ,  MALENKOVICH NELLY ,  WOOD CLIVE

IPC: A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  A61P3/10 ,  A61P11/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/08 ,  C07K14/705 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/566 ,  G01N33/573 ,  G01N33/68 ,  A61K38/00

CPC classification number: G01N33/6854 ,  G01N33/5014 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/573 ,  G01N2800/52

Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.

Abstract translation: 本发明提供分离的核酸分子，命名为PD-L2核酸分子，其编码作为PD-1配体的新型B7相关分子。 本发明还提供了反义核酸分子，含有PD-L2核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及已导入或破坏了PD-L2基因的非人类转基因动物。 本发明进一步提供分离的PD-L2多肽，融合蛋白，抗原肽和抗-PD-L2抗体。 本发明还提供了促进或抑制PD-L2与PD-1之间相互作用的方法。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：WO0114557B1

公开(公告)日：2001-04-19

申请号：PCT/US0023347

申请日：2000-08-23

Applicant: DANA FARBER CANCER INST INC ,  GENETICS INST

Inventor： WOOD CLIVE ,  FREEMAN GORDON J

IPC: G01N33/50 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61K45/00 ,  A61K45/06 ,  A61P1/16 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P15/06 ,  A61P19/02 ,  A61P21/04 ,  A61P25/00 ,  A61P25/28 ,  A61P29/00 ,  A61P31/06 ,  A61P31/12 ,  A61P31/16 ,  A61P31/18 ,  A61P31/20 ,  A61P31/22 ,  A61P33/06 ,  A61P33/12 ,  A61P35/00 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A61P37/08 ,  A61P41/00 ,  C07K14/705 ,  C07K16/28 ,  C12N15/09 ,  C12N15/12 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/566 ,  A61K38/17

CPC classification number: C07K14/70532 ,  A61K38/00 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61K2039/55516 ,  C07K14/70503 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  G01N2333/70503 ,  G01N2500/04 ,  A61K2300/00

Abstract: The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in an immune cell resulting in modulation of the immune response.

Abstract translation: 本发明将PD-1鉴定为B7-4的受体。 B7-4可以在结合免疫细胞上的抑制性受体时抑制免疫细胞活化。 因此，本发明提供用于调节PD-1，B7-4以及B7-4和PD-1之间的相互作用的试剂，以调节免疫细胞中的共刺激或抑制性信号，从而导致免疫应答的调节。

公开(公告)号：WO0200730A2

公开(公告)日：2002-01-03

申请号：PCT/US0120964

申请日：2001-06-28

Applicant: GENETICS INST ,  DANA FARBER CANCER INST INC

Inventor： FREEMAN GORDON ,  CHERNOVA IRENE ,  CHERNOVA TATYANA ,  MALENKOVICH NELLY ,  WOOD CLIVE

IPC: A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  A61P3/10 ,  A61P11/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/08 ,  C07K14/705 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/566 ,  G01N33/573 ,  G01N33/68 ,  C07N

CPC classification number: G01N33/6854 ,  G01N33/5014 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/573 ,  G01N2800/52

Abstract: The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.

Abstract translation: 本发明提供了分离的核酸分子，称为PD-L2核酸分子，其编码作为PD-1配体的新型B7相关分子。 本发明还提供了反义核酸分子，含有PD-L2核酸分子的重组表达载体，导入了表达载体的宿主细胞，以及导入或破坏了PD-L2基因的非人转基因动物。 本发明进一步提供了分离的PD-L2多肽，融合蛋白，抗原肽和抗PD-L2抗体。 本发明还提供了促进或抑制PD-L2与PD-1相互作用的方法。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：WO0200692A2

公开(公告)日：2002-01-03

申请号：PCT/US0120858

申请日：2001-06-28

Applicant: GENETICS INST ,  DANA FARBER CANCER INST INC ,  BRIGHAM & WOMENS HOSPITAL

Inventor： FREEMAN GORDON ,  CHERNOVA IRENE ,  CHERNOVA TATYANA ,  MALENKOVICH NELLY ,  WOOD CLIVE ,  LATCHMAN YVETTE ,  SHARPE ARLENE H

IPC: A61K39/00 ,  A61K39/395 ,  A61K48/00 ,  A61P3/10 ,  A61P11/06 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00 ,  A61P37/08 ,  C07K14/705 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12P21/02 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/53 ,  G01N33/566 ,  G01N33/573 ,  G01N33/68 ,  C07K14/00

CPC classification number: G01N33/6854 ,  G01N33/5014 ,  G01N33/505 ,  G01N33/5052 ,  G01N33/573 ,  G01N2800/52

Abstract: The invention provides isolated nucleic acid molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.

Abstract translation: 本发明提供分离的核酸分子，称为PD-L2核酸分子，其编码作为PD-1配体的新型B7相关分子。 本发明还提供了反义核酸分子，含有PD-L2核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及已导入或破坏了PD-L2基因的非人类转基因动物。 本发明进一步提供分离的PD-L2多肽，融合蛋白，抗原肽和抗-PD-L2抗体。 本发明还提供了促进或抑制PD-L2与PD-1之间相互作用的方法。 还提供了利用本发明组合物的诊断和治疗方法。

公开(公告)号：WO0158954A9

公开(公告)日：2003-01-16

申请号：PCT/US0104238

申请日：2001-02-09

Applicant: INST GENETICS LLC

Inventor： WOOD CLIVE ,  CHAUDHARY DIVYA ,  LONG ANDREW

IPC: C12N15/09 ,  A61K31/7088 ,  A61K38/00 ,  A61K39/395 ,  A61K48/00 ,  A61P1/00 ,  A61P9/10 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07K14/715 ,  C12N5/06 ,  C12N15/12 ,  C12Q1/02 ,  C07K16/28 ,  C12N15/62

CPC classification number: C07K14/715 ,  C07K2319/00

Abstract: The present invention relates, at least in part, to methods of modulating proliferation and apoptotic state of cells using agents that modulate the expression and/or activity of TRADE family polypeptides. In addition, the invention provides two novel members of the TRADE family of molecules.

Abstract translation: 本发明至少部分地涉及使用调节TRADE家族多肽的表达和/或活性的试剂调节细胞的增殖和凋亡状态的方法。 此外，本发明提供了TRADE家族分子的两个新成员。